CytoSorbents Appoints Thomas Bocchino as Chief Financial

CytoSorbents Appoints Thomas Bocchino as Chief Financial Officer 
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 11/30/12 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care-focused company using
blood purification to reduce inflammation as a means to prevent or
treat organ failure caused by life-threatening illnesses, announced
today that it has appointed Thomas Bocchino as Chief Financial
Mr. Bocchino, 53, brings to CytoSorbents more than 25 years of
financial and operational experience. Most recently, he was the CFO
of New Brunswick Scientific Co., Inc., (NBS) a manufacturer and
international distributor of laboratory equipment with more than
$100M in worldwide sales, particularly in the United States, Europe,
and Asia. He helped lead NBS as a NASDAQ Global Markets listed
company and oversaw its acquisition in 2007 by the international
laboratory supply conglomerate, Eppendorf AG, based out of Hamburg,
Germany. Mr. Bocchino remained the CFO of the NBS subsidiary until
this year. Prior to that, he held a number of financial positions,
including the CFO of IVC Industries, a publicly-traded manufacturer
of nutritional supplements, with revenues of approximately $70M, and
helped to engineer a financial turnaround of the company and
subsequent sale to Inverness Medical Innovations, Inc. Mr. Bocchino
earned his BS in Business Administration from the University of
Dayton and is a Certified Public Accountant and a Chartered Global
Management Accountant. 
Commenting on the appointment, Dr. Phillip Chan, Chief Executive
Officer said, "We are thrilled that Tom is joining us. As we look to
advance our commercial efforts, Tom brings a wealth of experience to
the Company in many different areas. For example, Tom's outstanding
expertise in international finance and distribution, particularly in
the European Union, will be instrumental as we geographically expand
CytoSorb(R) cartridge sales. At NBS, he helped to build and manage a
worldwide network of distributors and direct sales offices that
generated more than $100M in revenue, and is expected to make
significant contributions in implementing our own similar strategy.
Tom's experience as a global markets public company CFO, including
Securities and Exchange Commission and Sarbanes Oxley compliance,
governance, and reporting will be invaluable as we work towards a
stock exchange up-listing. Additionally, his outward facing
interactions with the analyst and investor communities will be
important in helping to execute our financing strategy." 
Al Kraus, Chairman of the Board stated, "Tom is the right person at
the right time for our Company. He is a talented and seasoned senior
executive and we are delighted to welcome him to the management team.
We look forward to his many anticipated contributions."  
Mr. Bocchino commented, "This is a very exciting time for
CytoSorbents, with the potential to save lives with CytoSorb(R), and
to capitalize on so many other different near-term opportunities. I
am very pleased to have a chance to bring my financial and
international experience to help make CytoSorbents a commercial
Dr. Chan stated, "As we welcome Tom, on behalf of the Company and the
Board of Directors, we also would like to thank Mr. Ronald Berger,
who has done an outstanding job as our Interim CFO. His hard work,
dedication, and many accomplishments over the past eight years as
Interim CFO and Controller with the Company are greatly appreciated.
We look forward to continuing to work with both Tom and Ron in the
About CytoSorbents  
CytoSorbents Corporation is a critical care focused therapeutic
device company using blood purification to modulate the immune system
and fight multi-organ failure in life-threatening illnesses. Its
purification technology is based on biocompatible, highly porous
polymer beads that can actively remove toxic substances from blood
and other bodily fluids by pore capture and adsorption. CytoSorb(R),
the Company's flagship product, is approved in the European Union as
a safe and effective cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as sepsis,
burn injury, trauma, lung injury, and pancreatitis. These are
conditions where the mortality is extremely high, yet no effective
treatments exist. Additional information is available on the
Company's website: 
Forward-Looking Statements  
This press release includes forward-looking statements intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements
in this press release are not promises or guarantees and are subject
to risks and uncertainties that could cause our actual results to
differ materially from those anticipated. These statements are based
on management's current expectations and assumptions and are
naturally subject to uncertainty and changes in circumstances. We
caution you not to place undue reliance upon any such forward-looking
statements. Actual results may differ materially from those expressed
or implied by the statements herein. CytoSorbents Corporation and
CytoSorbents, Inc believe that its primary risk factors include, but
are not limited to: obtaining government approvals including required
FDA and additional CE Mark approvals; ability to successfully develop
commercial operations; dependence on key personnel; acceptance of the
Company's medical devices in the marketplace; the outcome of pending
and potential litigation; compliance with governmental regulations;
reliance on research and testing facilities of various universities
and institutions; the ability to obtain adequate and timely financing
in the future when needed; product liability risks; limited
manufacturing experience; limited marketing, sales and distribution
experience; market acceptance of the Company's products; competition;
unexpected changes in technologies and technological advances; and
other factors detailed in the Company's Form 10-K filed with the SEC
on March 30, 2012, which is available at  
CytoSorbents Corporation
Dr. Phillip Chan 
Chief Executive Officer 
(732) 329-8885 ext. *823 
Press spacebar to pause and continue. Press esc to stop.